UNSPSC 51332869: Pipotiazine undecylenate

This classification denotes an antipsychotic agent C35H51N3O4S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5XL1XX5J17, chemically known as 10-undecenoic acid,2-(1-(3-(2-((dimethylamino)sulfonyl)-10h-phenothiazin-10-yl)propyl)-4-piperidinyl)ethyl ester, but more generally known as pipotiazine undecylenate, which bears US NIH Compound Identifier 89615. European Medicines Agency schedules Pipotiazine undecylenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03861MIG.

Most nations, for tariff and trade purposes, schedule pipotiazine undecylenate under HS 29350090 and SITC 51580. As of Q4 2014, PIPOTIAZINE UNDECYLENATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)S(=O)(=O)C1CCC2C(C1)N(C3CCCCC3S2)CCCN4CCC(CC4)CCOC(=O)CCCCCCCCC=C.

UNSPSC 51332869 Pipotiazine undecylenate is a Commodity code that in recent state and local procurement shows little direct activity matching its narrow pharmaceutical specification. The three recent opportunities tagged under this code—Seminole County's naloxone and drug deactivation systems procurement, the Texas HHS Commission's therapeutic pharmacy initiative RFI, and the Minnesota Multistate Cooperative Purchasing Alliance's generic multi-source pharmaceuticals and OTC products RFP—address broader pharmaceutical procurement, supply chain management, and community health initiatives rather than pipotiazine undecylenate specifically. The issuing bodies span county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and multistate cooperative purchasing vehicles (Minnesota Department of Administration). Work solicited under the code encompasses naloxone distribution, direct-to-manufacturer prescription programs, and cooperative purchasing arrangements for generic pharmaceuticals and OTC products, with vendors expected to meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act requirements, and specified insurance coverage thresholds.

Activity concentrates in Florida, Texas, and Minnesota, with the Minnesota cooperative extending to Oregon. Seminole County's IFB 60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023 (note: deadline appears historically dated in source). The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, gathers vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and group purchasing organization channels, with no formal award timeline specified at the exploratory phase. The Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802, posted January 20, 2026, establishes multiple contracts for generic pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, a July 1, 2026 effective date for awarded vendors, and price competitiveness weighted at 75 percent of evaluation. All three procurements require electronic submission, E-Verify compliance, and adherence to federal manufacturing and supply-chain security standards.